Nuvalent, Inc.
NUVL
Kedudukan dalam Saham
#2094
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Harga Saham
$123.96
Disegerakkan terakhir: 2026-07-21
Modal Pasaran
$9.75B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
36.40%
Negara
US
Perdagangan Nuvalent, Inc. (NUVL)
Kategori
Healthcare
Sejarah harga saham bagi Nuvalent, Inc. (NUVL)
Harga penutupan tertinggi: $123.86 pada 2026-07-01
Harga penutupan terendah: $18.50 pada 2021-07-01
Harga penutupan terendah: $18.50 pada 2021-07-01
Sejarah harga saham Nuvalent, Inc. dari 2021 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | 0.78% |
| 2025 | 19.50% |
| 2024 | 20.56% |
| 2023 | 136.75% |
| 2022 | 51.32% |
| 2021 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
